In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BeyondSpring raises $15.25mm through Series B round

Executive Summary

BeyondSpring Inc. raised $15.25mm through its Series B round. Investors included Epiphron Capital Fund, Broad Resources Value and Growth, Suzhou Broad Resources Ling Long Private Equity, Beijing Huarong Sangel Venture Capital, and individual investors, including the president of a division of Fosun. BeyondSpring is developing cancer therapies, and has its lead candidate plinabulin in Phase II and III trials for non-small cell lung cancer and prevention of chemotherapy-induced neutropenia.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies